D. Boral Capital Reiterates “Buy” Rating for Cytosorbents (NASDAQ:CTSO)

D. Boral Capital restated their buy rating on shares of Cytosorbents (NASDAQ:CTSO) in a research report sent to investors on Friday,Benzinga reports. The firm currently has a $10.00 price target on the medical research company’s stock.

Several other research firms have also issued reports on CTSO. HC Wainwright reissued a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a research report on Monday, November 11th. StockNews.com began coverage on shares of Cytosorbents in a research note on Saturday, December 28th. They set a “hold” rating for the company. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Cytosorbents currently has a consensus rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Trading Up 1.8 %

Shares of NASDAQ:CTSO opened at $0.94 on Friday. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. The company has a market capitalization of $51.21 million, a PE ratio of -2.60 and a beta of 0.58. Cytosorbents has a 12-month low of $0.70 and a 12-month high of $1.59. The business’s fifty day simple moving average is $0.92 and its 200-day simple moving average is $1.02.

Institutional Investors Weigh In On Cytosorbents

Several institutional investors have recently added to or reduced their stakes in CTSO. Atomi Financial Group Inc. acquired a new stake in Cytosorbents in the 3rd quarter worth approximately $51,000. Geode Capital Management LLC increased its stake in Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares in the last quarter. Finally, Sargent Investment Group LLC raised its holdings in shares of Cytosorbents by 4.9% in the second quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after buying an additional 67,181 shares during the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.